City Therapeutics is set for commercialization momentum beyond its liver-focused roots after pricing a $200 million IPO to fund an expansion of its RNA interference pipeline. The company says the proceeds will support a trio of therapies in or near clinical testing, alongside earlier programs aimed at enabling RNAi delivery outside the liver.